UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction | (Commission | (IRS Employer |
of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) (Zip Code)
(
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Trading | | Name of each exchange | |
Title of each class | Symbol(s) | on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 14, 2026, Harmony Biosciences Holdings, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 50,381,309 shares of the Company’s common stock were represented in person or by proxy, constituting a quorum. At the Annual Meeting, stockholders voted on the following three proposals, each of which is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on April 3, 2026.
Proposal 1. The election of four Class III directors listed below to serve until the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
Votes For | Withheld | Broker Non-Votes | |
Geno Germano | 44,963,163 | 1,524,142 | 3,894,004 |
Troy Ignelzi | 32,813,495 | 13,673,810 | 3,894,004 |
Ron Philip | 31,826,838 | 14,660,467 | 3,894,004 |
Andreas Wicki, Ph.D. | 25,114,526 | 21,372,779 | 3,894,004 |
Based on the votes set forth above, each of the director nominees was duly elected.
Proposal 2. The ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Votes For | Votes Against | Abstain |
49,385,510 | 830,697 | 165,102 |
Based on the votes set forth above, the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ended December 31, 2026, was duly ratified.
Proposal 3. The approval on a non-binding, advisory basis, of the compensation of the Company’s named executive officers pursuant to the SEC’s compensation disclosure rules.
For | Against | Abstain | Broker Non-Vote |
33,249,862 | 13,042,898 | 194,545 | 3,894,004 |
Based on the votes set forth above, the shareholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers pursuant to the SEC’s compensation disclosure rules.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HARMONY BIOSCIENCES HOLDINGS, INC. | ||
Date: May 14, 2026 | By: | /s/ Christian Ulrich |
Christian Ulrich | ||
EVP and General Counsel | ||